AssetMark Inc
TGTX icon

AssetMark Inc’s TG Therapeutics TGTX Stock Holding History

AssetMark Inc’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.89K Buy
180
+65
+57% +$2.66K ﹤0.01% 2453
2026
Q1 		$3.82K Buy
115
+2
+2% +$60 ﹤0.01% 2665
2025
Q4 		$3.37K Buy
113
+11
+11% +$359 ﹤0.01% 2606
2025
Q3 		$3.69K Sell
102
-5
-5% -$165 ﹤0.01% 2438
2025
Q2 		$3.85K Buy
107
+16
+18% +$596 ﹤0.01% 2216
2025
Q1 		$3.59K Hold
91
– – ﹤0.01% 2059
2024
Q4 		$2.74K Hold
91
– – ﹤0.01% 2052
2024
Q3 		$2.13K Buy
+91
New +$1.99K ﹤0.01% 1878

Other funds holding TGTX

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AssetMark Inc's TGTX Position: Q2 2026 in Review

AssetMark Inc increased its TG Therapeutics (TGTX) stake by 57% in Q2 2026, buying an estimated $2.66K and bringing the position to 180 shares worth $9.89K. The position accounts for ﹤0.01% of the portfolio, ranked #2453.

AssetMark Inc first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • AssetMark Inc held 180 shares of TG Therapeutics worth $9.89K as of Q2 2026.
  • AssetMark Inc bought 65 TG Therapeutics shares in Q2 2026, an estimated $2.66K.
  • TG Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2453 holding.
  • AssetMark Inc first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.